8/1/2014 10:08:38 AM
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), today announced that Pfizer and Roche have joined the ADDPLAN® DF Consortium. The consortium was founded in 2013 by Novartis Pharma AG, Janssen Pharmaceuticals Inc., Eli Lilly, and Aptiv Solutions, which is an ICON plc company leading the design and implementation of adaptive trials. The goal of the ADDPLAN DF Consortium is to develop methodologies and execution technologies that improve dose-selection, which remains a major barrier to resolving high failure rates in Phase III trials. Both Pfizer’s and Roche’s decision to join the Consortium comes as more companies recognise the value of adaptive design in improving decision making in exploratory development.
Help employers find you! Check out all the jobs and post your resume.
comments powered by